

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Cost Comparison Appraisal

Tenecteplase for treating acute ischaemic stroke [ID6306]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (tenecteplase) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Arrhythmia Alliance • Blood Pressure UK (formerly Blood Pressure Association) • Brain and Spinal Injury Charity (BASIC) • Brain and Spine Foundation • Brain Charity • British Cardiac Patients Association • Cardiovascular Care Partnership • Circulation Foundation • Different Strokes • HEART UK • Neurological Alliance • Pumping Marvellous Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Stroke Information • Thrombosis UK <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of British Clinical Diabetologists • Association of British Neurologists • British and Irish Association of Stroke Physicians • British and Irish Hypertension Society • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Neuropathological Society • British Society for Haematology 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Government Stroke Implementation Group • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (alteplase) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Society for Cardiovascular Research • Cochrane Stroke Group • Cochrane UK • European Council for Cardiovascular Research • Genomics England

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Society for Haemostasis and Thrombosis • British Society of Cardiovascular Imaging • British Society of Neuroradiologists • Clinical Leaders of Thrombosis (CLOT) • Haemochromatosis UK • Institute of Neurology • National Heart and Lung Institute • National Neurosciences Advisory Group • Primary Care and Community Neurology Society • Primary Care Cardiovascular Society • Primary Care Diabetes Society • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society of British Neurological Surgeons • Society of Vascular Nurses • The Vascular Society of Great Britain and Ireland • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • King's College London Stroke Programme • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • The Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.